Cargando…
Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients
Metallothioneins (MT) are ubiquitous, intracellular small proteins with high affinity for heavy metal ions. In the last decades, it was shown that MT overexpression in a variety of cancers is associated with resistance to anticancer drugs and is combined with a poor prognosis. In this prospective st...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361379/ https://www.ncbi.nlm.nih.gov/pubmed/16508630 http://dx.doi.org/10.1038/sj.bjc.6603028 |
_version_ | 1782153202036113408 |
---|---|
author | Weinlich, G Eisendle, K Hassler, E Baltaci, M Fritsch, P O Zelger, B |
author_facet | Weinlich, G Eisendle, K Hassler, E Baltaci, M Fritsch, P O Zelger, B |
author_sort | Weinlich, G |
collection | PubMed |
description | Metallothioneins (MT) are ubiquitous, intracellular small proteins with high affinity for heavy metal ions. In the last decades, it was shown that MT overexpression in a variety of cancers is associated with resistance to anticancer drugs and is combined with a poor prognosis. In this prospective study, we examined the role of MT overexpression in melanoma patients as a prognostic factor for progression and survival. Between 1993 and 2004, 3386 patients with primary cutaneous melanoma were investigated by using a monoclonal antibody against MT on routinely fixed, paraffin-embedded tissues. In all, 1270 patients could be followed up for further statistical analysis (Fisher's exact test, Mantel–Haenszel χ(2) test, Kaplan–Meier curves). The MT data of disease-free interval and overall survival were compared univariately and multivariately in Cox regression analysis. Immunohistochemical overexpression of MT in tumour cells of patients with primary melanoma (310 of 1270; 24.4%) was associated with a higher risk for progression (117 of 167; 70.1%) and reduced survival (80 of 110; 72.7%) of the disease (P<0.0001). Similarly, Kaplan–Meier curves gave highly significant disadvantages for the MT-positive group. Univariate analysis (relative risk 7.4; 95% confidence interval (CI) 5.2–10.2; P<0.0001 for progression; relative risk 7.1; 95% CI 4.7–10.9; P<0.0001 for survival), as well as multivariate analysis with other prognostic markers resulted in MT overexpression as a highly significant and independent factor for prognosis in primary melanoma. |
format | Text |
id | pubmed-2361379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23613792009-09-10 Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients Weinlich, G Eisendle, K Hassler, E Baltaci, M Fritsch, P O Zelger, B Br J Cancer Clinical Study Metallothioneins (MT) are ubiquitous, intracellular small proteins with high affinity for heavy metal ions. In the last decades, it was shown that MT overexpression in a variety of cancers is associated with resistance to anticancer drugs and is combined with a poor prognosis. In this prospective study, we examined the role of MT overexpression in melanoma patients as a prognostic factor for progression and survival. Between 1993 and 2004, 3386 patients with primary cutaneous melanoma were investigated by using a monoclonal antibody against MT on routinely fixed, paraffin-embedded tissues. In all, 1270 patients could be followed up for further statistical analysis (Fisher's exact test, Mantel–Haenszel χ(2) test, Kaplan–Meier curves). The MT data of disease-free interval and overall survival were compared univariately and multivariately in Cox regression analysis. Immunohistochemical overexpression of MT in tumour cells of patients with primary melanoma (310 of 1270; 24.4%) was associated with a higher risk for progression (117 of 167; 70.1%) and reduced survival (80 of 110; 72.7%) of the disease (P<0.0001). Similarly, Kaplan–Meier curves gave highly significant disadvantages for the MT-positive group. Univariate analysis (relative risk 7.4; 95% confidence interval (CI) 5.2–10.2; P<0.0001 for progression; relative risk 7.1; 95% CI 4.7–10.9; P<0.0001 for survival), as well as multivariate analysis with other prognostic markers resulted in MT overexpression as a highly significant and independent factor for prognosis in primary melanoma. Nature Publishing Group 2006-03-27 2006-02-28 /pmc/articles/PMC2361379/ /pubmed/16508630 http://dx.doi.org/10.1038/sj.bjc.6603028 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Weinlich, G Eisendle, K Hassler, E Baltaci, M Fritsch, P O Zelger, B Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients |
title | Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients |
title_full | Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients |
title_fullStr | Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients |
title_full_unstemmed | Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients |
title_short | Metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients |
title_sort | metallothionein – overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361379/ https://www.ncbi.nlm.nih.gov/pubmed/16508630 http://dx.doi.org/10.1038/sj.bjc.6603028 |
work_keys_str_mv | AT weinlichg metallothioneinoverexpressionasahighlysignificantprognosticfactorinmelanomaaprospectivestudyon1270patients AT eisendlek metallothioneinoverexpressionasahighlysignificantprognosticfactorinmelanomaaprospectivestudyon1270patients AT hasslere metallothioneinoverexpressionasahighlysignificantprognosticfactorinmelanomaaprospectivestudyon1270patients AT baltacim metallothioneinoverexpressionasahighlysignificantprognosticfactorinmelanomaaprospectivestudyon1270patients AT fritschpo metallothioneinoverexpressionasahighlysignificantprognosticfactorinmelanomaaprospectivestudyon1270patients AT zelgerb metallothioneinoverexpressionasahighlysignificantprognosticfactorinmelanomaaprospectivestudyon1270patients |